Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.
Advertisement
Articles by Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5